Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2405-2411

  Fujii, Toshiyuki ^a   Tachibana, Mitsuo ^a   Dhar, Dipok Kumar ^a   Ueda, Shuhei ^a   Kinugasa, Shoichi ^a   Yoshimura, Hiroshi ^a   Kohno, Hitoshi ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Colorectal cancer; Paclitaxel; Thalidomide; Xenograft

Indexed keywords

PACLITAXEL; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; COLONIC NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0042807635     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-43, 2001.
2. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6: 2635-2643, 2000.
3. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K et al: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28: 62-6, 2001.
4. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
5. Rajkumar SV: Current status of thalidomide in the treatment of cancer. Oncology 15: 867-874, 2001.
6. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 26: 4082-5, 1994.
7. Kinuya S, Kawashima A, Yokoyama K, Koshida K, Konishi S, Watanabe N et al: Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med 43: 1084-9, 2002.
8. Kotoh T, Dhar DK, Masunaga R, Tabara H, Tachibana M, Kubota H et al: Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 125: 536-44, 1999.
9. Myoung H, Hong SD, Kim YY, Hong SP and Kim MJ: Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 163: 191-200, 2001.
10. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK et al: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92: 2364-73, 2000.
11. Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'Dwyer PJ et al: Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group Trial (PA286). Am J Ther 3: 750-754, 1996.
12. Huang K, Vaughn DJ, Shaw LM, Recio A, Bonner HS and Haller DG: A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer. Am J Clin Oncol 21: 548-52, 1998.
13. Gluck S, Germond C, Lopez P, Cano P, Dorreen M, Koski T et al: A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. Er J Cancer 34: 1008-14, 1998.
14. Pignata S, Frezza P, Tramontana S, Perrone F, Tambaro R, Casella G et al: Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol 11: 455-9, 2000.
15. Guian P, Shaw M, Mirochnik Y, Slobodsky L, Ray V and Rubenstein M: Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Meth Find Exp Clin Pharmacol 20: 739-742, 1998.
16. Dhar DK, Ono T, Yamanoi A, Soda Y, Yamaguchi E, Rahman MA et al: Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 95: 188-195, 2002.
17. Vivat-Hannah V, You D, Rizzo C, Daris JP, Lapointe P, Zusi FC et al: Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Res 61: 8703-11, 2001.
18. Verheul HMW, Panigrahy D, Tuan J and D'Amato RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 79: 114-118, 1999.
19. Kennedy AS, Harrison GH, Mansfield CM, Zhou XJ, Xu JF and Balcer-Kubiczek EK: Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency. Int J Cancer 90: 175-85, 2000.
20. van Bree C, Savonije JH, Franken NA, Haveman J and Bakker PJ: The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 16: 739-44, 2000.
21. Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O and Klausner JM: Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 16: 3673-7, 1996.
22. Rajkumar SV, Gertz MA and Witzig TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343: 972-3, 2000.
23. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K et al: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28: 62-6, 2001.
24. Gavindarajan R, Heaton KH, Broadwater R, Zeitlin A, Lang NP and Hauer-Jensen M: Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356: 566-567, 2000.
25. Rose WC, Long BH, Fairchild CR, Lee FY and Kadow JF: Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 7: 2016-21, 2001.
26. Lau DH, Xue L, Young LJ, Burke PA and Cheung AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14: 31-6, 1999.
27. McCarty MF: Thalidomide may impede cell migration in primate by down-regulating integrin b-chains: potential therapeutic utility in solid malignancies, prolifertive retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Medical Hypothesis 49: 123-131, 1997.
28. Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-92, 1998.